Xenon Pharmaceuticals (XENE): Growth-Adjusted P/E Ratio
Xenon Pharmaceuticals (XENE) is valued as a leading innovator in neuroscience. The PEG ratio visualizes the market consensus on business growth rates, where 0.00 serves as the current parameter value. Financial stability relies on the non-cyclical nature of epilepsy research, although cash flows remain volatile prior to product commercialization. Investors must account for the risks associated with the clinical trial stage.
Metric breakdowns and analytics for Xenon Pharmaceuticals (XENE)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Xenon Pharmaceuticals|XENE - Long-Term Debt to Equity|Current Liabilities to Equity Xenon|XENE - Company Aggregate Debts|Debt to Net Assets Ratio Xenon Corp|XENE - Company Long-Term Debts|Company Short-Term Debts Xenon Pharmaceuticals|Intermediate Coverage Ratio xenon-pharma.com
- earnings and multiples data:
XENE - Company Net Income|Future Profit Xenon Pharmaceuticals|XENE - P/E Multiple|Forward P/E Multiple Xenon Pharmaceuticals|XENE - PEG Multiple|Enterprise Value to EBITDA Ratio Xenon Corp|XENE - Operating profit EBITDA|Net earnings per one share for the last twelve months Xenon Pharmaceuticals|XENE - Net earnings per share for the last 12 months|Quarterly EPS earnings growth xenon-pharma.com|XENE - Net earnings per share growth this year|Projected earnings per share increase next year Xenon Pharmaceuticals
- total revenue and sales volume data:
General company analysis:Xenon Pharmaceuticals Inc, XENE
The PEG ratio compares the market value of earnings to their growth rate, allowing for the identification of undervalued assets when the value is below one. By analyzing this PEG chart, an investor can assess the extent to which the clinical trial ethics and laboratory energy efficiency of Xenon Pharmaceuticals (XENE) translate into sustainable business expansion, determining whether the stock has "rocket" potential or is signaling a slowdown.
Competing companies
Growth-Adjusted Market Cap to Net Income Biogen Idec|Neurocrine Corp - Price/Earnings to Growth Multiple|regencellbioscience.com (RGC) - Price to Earnings Adjusted for Growth Rate|AXSM - Price/Earnings to Growth Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Growth-Adjusted P/E Ratio|Viking Therapeutics (VKTX) - Price/Earnings to Growth Ratio|Supernus Corp - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple CPRX|Denali Therapeutics Inc. (DNLI) - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Multiple HRMY (Harmony Corp)|BHVN - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Amylyx Pharmaceuticals, Inc. AMLX|Growth-Adjusted Payback Ratio TRVI|PRAX - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income Anavex Life Sciences AVXL|CBLL: PEG Multiple|Price/Earnings to Growth Multiple Prothena Corporation PLC|ALEC (alector.com) - PEG Multiple|Price/Earnings to Growth Multiple Annexon, Inc. (ANNX)|Price/Earnings to Growth Ratio Omeros Corporation (OMER)|Neurogene Inc. - Growth-Adjusted P/E Ratio|acimmune.com - Price/Earnings to Growth Multiple|PEG Multiple Voyager Therapeutics Inc VYGR|NMRA - Price/Earnings to Growth Ratio|Price to Net Income Growth Ratio Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio ACOG|Price/Earnings to Growth Ratio Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple SAVA (Cassava)|Growth-Adjusted Market Cap to Net Income Assertio Therapeutics|Coya Therapeutics, Inc. - Price/Earnings to Growth Multiple|Company Value to Earnings Growth Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - PEG Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Price/Earnings to Growth Multiple|CRVO (CervoMed, Inc.) - Price/Earnings to Growth Multiple|Price/Earnings to Growth Multiple Alterity Therapeutics Ltd|Price/Earnings to Growth Ratio Clene Inc.|PepGen Inc. - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple JUNS (Jupiter Neurosciences Inc)|Price/Earnings to Growth Ratio RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income Grace Tx (GRCE)|fireflyneuro.com - PEG Multiple|Klotho Neurosciences (KLTO) - Price/Earnings to Growth Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio RVPH (Reviva Pharmaceuticals Holdings, Inc.)|MTVA (MetaVia) - PEG Multiple|NRXS: Growth-Adjusted Payback Ratio|PEG Multiple HSDT|PEG Multiple Passage Bio Inc. (PASG)|Price/Earnings to Growth Ratio bionomics.com.au NEUP|PEG Multiple Minerva Neurosciences Inc NERV|ATHA: Price/Earnings to Growth Multiple|ADXN (Addex Therapeutics, Ltd.) - Growth-Adjusted P/E Ratio|Alzamend Neuro Inc. (ALZN) - Price/Earnings to Growth Ratio|Cyclerion - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio protagenic.com|Pasithea Therapeutics - Market Cap to Earnings and Growth Ratio|Price/Earnings to Growth Multiple CRGT (Cortigent, Inc.)|Avenue Therapeutics - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Brainstorm Cell BCLI|PEG Multiple caratherapeutics.com CARA|Chromocell Therapeutics Corp. - PEG Multiple|eliemtx.com - Company Value to Earnings Growth Ratio|Intra-Cellular Therapies (ITCI) - Price/Earnings to Growth Ratio|LBPH (Longboard) - Price/Earnings to Growth Ratio|MRNS (marinuspharma.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate NKGen Biotech NKGN|Price/Earnings to Growth Ratio NeuroBo Pharma (NRBO)|Company Value to Earnings Growth Ratio SAGE|Synaptogenix, Inc. - Price/Earnings to Growth Multiple|TRVN: Growth-Adjusted P/E Ratio|VIGL - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio WENA (Anew Medical, Inc.)|CERE: PEG Multiple
